Newsroom

Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS^® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting

Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 2019

Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis

Takeda Presents 18-Month Data from Pivotal Phase 3 Trial of Dengue Vaccine Candidate at the American Society of Tropical Medicine and Hygiene (ASTMH) 68^th Annual Meeting

Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG^® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up